このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

原発性シェーグレン症候群(pSS)の成人におけるニポカリマブの研究

2026年10月15日 更新者:Janssen Research & Development, LLC

原発性シェーグレン症候群(pSS)の成人におけるニポカリマブの有効性と安全性を評価するための無作為化プラセボ対照二重盲検多施設試験

The purpose of this study is to evaluate the efficacy and safety of nipocalimab in participants with primary Sjogren's syndrome (pSS) versus placebo.

調査の概要

研究の種類

介入

入学 (実際)

163

段階

  • フェーズ2

アクセスの拡大

一時的に利用できません 臨床試験外。 拡張アクセス記録をご覧ください。

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Anniston、Alabama、アメリカ、36207
        • Anniston Medical Clinic
    • Arizona
      • Glendale、Arizona、アメリカ、85306
        • Arizona Arthritis and Rheumatology Research PLLC
      • Mesa、Arizona、アメリカ、85210
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Fullerton、California、アメリカ、92835
        • St. Jude Heritage Medical Group
      • Upland、California、アメリカ、91786
        • Inland Rheumatology Clinical Trials, Inc.
    • Colorado
      • Denver、Colorado、アメリカ、80230
        • Denver Arthritis Clinic
      • Denver、Colorado、アメリカ、80228
        • Colorado Arthritis Associates
    • Florida
      • Boca Raton、Florida、アメリカ、33486
        • Rheumatology Associates Of South Florida
      • Brandon、Florida、アメリカ、33511
        • Bay Area Arthritis and Osteoporosis
      • Fort Lauderdale、Florida、アメリカ、33309
        • Centre for Rheumatology, Immunology and Arthritis
      • Jacksonville、Florida、アメリカ、32209
        • University of Florida Health Jacksonville
      • Orlando、Florida、アメリカ、32835
        • Omega Research Consultants
    • Illinois
      • Gurnee、Illinois、アメリカ、60031
        • Clinical Investigation Specialists
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • University of Kansas Medical Center
    • Minnesota
      • Eagan、Minnesota、アメリカ、55121
        • St. Paul Rheumatology P A
    • Mississippi
      • Tupelo、Mississippi、アメリカ、38801
        • North Mississippi Medical Clinics
    • North Carolina
      • Salisbury、North Carolina、アメリカ、28144
        • PMG Research of Salisbury
    • Pennsylvania
      • Duncansville、Pennsylvania、アメリカ、16635
        • Altoona Center For Clinical Research
      • Philadelphia、Pennsylvania、アメリカ、19104
        • University of Pennsylvania
    • South Carolina
      • Columbia、South Carolina、アメリカ、29204
        • Columbia Arthritis Center
    • Tennessee
      • Jackson、Tennessee、アメリカ、38305
        • West Tennessee Research Institute
      • Memphis、Tennessee、アメリカ、38119
        • Dr. Ramesh Gupta
    • Texas
      • Austin、Texas、アメリカ、78731-3146
        • Austin Regional Clinic
      • Carrollton、Texas、アメリカ、75007
        • Trinity Clinical Research, LLC
      • Brescia、イタリア、25123
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
      • Catania、イタリア、95100
        • P.O. Vittorio Emanuele Azienda Ospedaliero Universitaria 'Policlinico Vittorio Emanuele'
      • Milan、イタリア、20132
        • IRCCS Ospedale San Raffaele
      • Palermo、イタリア、90129
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Verona、イタリア、37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Leeuwarden、オランダ、8934 AD
        • Medisch Centrum Leeuwarden
      • Rotterdam、オランダ、3015 GD
        • Erasmus Medisch Centrum
      • A Coruña、スペイン、15006
        • Hosp Univ A Coruna
      • Córdoba、スペイン、14004
        • Hosp Reina Sofia
      • Mérida、スペイン、6800
        • Hosp. de Merida
      • Sabadell、スペイン、08208
        • Corporacio Sanitari Parc Tauli
      • Salamanca、スペイン、37007
        • Hosp Clinico Univ de Salamanca
      • Seville、スペイン、41010
        • Hosp. Infanta Luisa
      • Berlin、ドイツ、10117
        • Charite Universitaetsmedizin Berlin
      • Cologne、ドイツ、50923
        • Uniklinik Köln
      • Dresden、ドイツ、01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Hamburg、ドイツ、20095
        • Hamburger Rheuma Forschungszentrum II
      • Kirchheim unter Teck、ドイツ、73230
        • medius KLINIK KIRCHHEIM
      • Tübingen、ドイツ、72076
        • Universitatsklinikum Tubingen
      • La Tronche、フランス、38700
        • CHU de Grenoble Hopital Albert Michallon
      • Le Mans、フランス、72037
        • Centre Hospitalier Le Mans
      • Marseille、フランス、13285
        • Hopital Saint Joseph
      • Paris、フランス、75013
        • Hopital Pitie Salpetriere
      • Strasbourg、フランス、67098
        • CHRU Hôpital de Hautepierre
      • Lisbon、ポルトガル、1050-034
        • Instituto Portugues de Reumatologia
      • Ponte de Lima、ポルトガル、4990-078
        • ULSAM, EPE - Hospital Conde de Bertiandos
      • Bydgoszcz、ポーランド、85-065
        • Nasz Lekarz Przychodnie Medyczne
      • Bydgoszcz、ポーランド、85-168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy
      • Gmina Końskie、ポーランド、26 200
        • Zespolu Opieki Zdrowotnej w Konskich
      • Krakow、ポーランド、30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Lublin、ポーランド、20-607
        • REUMED Zespol Poradni Specjalistycznych Filia nr 2
      • Poznan、ポーランド、61 113
        • Centrum Medyczne
      • Warsaw、ポーランド、00-874
        • Medycyna Kliniczna
      • Warsaw、ポーランド、02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw、ポーランド、03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw、ポーランド、52 415
        • Centrum Medyczne Oporow
      • Taipei、台湾、11490
        • Tri-Service General Hospital
      • Taoyuan、台湾、333
        • Chang Gung Memorial Hospital Linkou Branch
      • Fuchū、日本、183 8524
        • Tokyo Metropolitan Tama Medical Center
      • Nagasaki、日本、852-8501
        • Nagasaki University Hospital
      • Sapporo、日本、060-8648
        • Hokkaido University Hospital
      • Tokyo、日本、104 8560
        • St. Luke's International Hospital
      • Tokyo、日本、173 8610
        • Nihon University Itabashi Hospital
      • Tsukuba、日本、305-8520
        • University of Tsukuba Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Meets classification criteria for primary Sjogren's syndrome (pSS) by the 2016 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) at the time of screening (results either obtained during screening or documented in the participant's medical history are acceptable to fulfill these criteria for Schirmer's test, unstimulated salivary flow test, ocular staining score, or labial salivary gland biopsy), and was diagnosed with pSS no less than 26 weeks prior to screening
  • At screening is seropositive for antibodies to pSS-associated antigen A (Ro/Sjogren's syndrome-related antigen A [SSA])
  • Total Clinical European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (clinESSDAI) score greater than or equal to (>=) 6
  • At least one abnormal laboratory marker of pSS-related inflammatory disease activity, and at least low activity in one or more specified European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) domains
  • It is recommended to be up to date on all age-appropriate vaccinations prior to screening per routine local medical guidelines. It is strongly recommended that participants will have completed a locally-approved (or emergency use-authorized) coronavirus disease 2019 (COVID-19) vaccination regimen at least 2 weeks prior to study related visits or procedures. Study participants should, follow applicable local vaccine labelling, guidelines, and standards-of-care for participants receiving immune-targeted therapy will be followed when determining an appropriate interval between vaccination and study enrollment

Exclusion Criteria:

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her pSS or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
  • Comorbidities (for example, asthma, chronic obstructive pulmonary disease) which have required 3 or more courses of systemic glucocorticoids within the previous 12 months
  • Has any unstable or progressive manifestation of pSS that is likely to warrant escalation in therapy beyond permitted background medications and/or has severely active pSS
  • Has received oral cyclophosphamide within 3 months or intravenous (IV) cyclophosphamide within 6 months prior to first administration of study intervention
  • Has Sjogren's syndrome overlap syndromes where another confirmed autoimmune rheumatic or systemic inflammatory condition (for example, rheumatoid arthritis [RA], systemic lupus erythematosus [SLE], scleroderma, inflammatory bowel disease [IBD]) is the primary diagnosis or has clinical manifestations that, in the opinion of the investigator, or the sponsor or sponsor's representative, are likely to interfere with the investigator's ability to assess pSS manifestations

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Group 1: Placebo

Participants will receive placebo intravenously (IV) every 2 weeks (q2w) through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Placebo infusion will be administered intravenously.

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

実験的:Group 2: Nipocalimab Dose 1

Participants will receive nipocalimab dose 1 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

他の名前:
  • JNJ-80202135
  • M281
実験的:Group 3: Nipocalimab Dose 2

Participants will receive nipocalimab dose 2 IV q2w through Week 22 along with standard of care treatments ([including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues], and/or one immunomodulator with or without low-dose glucocorticosteroids).

Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally.

Nipocalimab dose 1 and dose 2 infusions will be administered intravenously.

他の名前:
  • JNJ-80202135
  • M281

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in Clinical European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (clinESSDAI) Score at Week 24
時間枠:Baseline (Week 0), Week 24

In clinESSDAI, physician scores systemic disease activity level on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 levels (no, low, moderate, high) according to their severity as assessed by investigator based on pre-defined criteria. The activity-level score ranges from 0 to 3, where 0=no disease activity and 3=high disease activity. Not all domain include all 4 activity level. Each domain was assigned weight between 1 and 7; activity-level score is multiplied by corresponding domain weight to obtain weighted domain score. Each domain has specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score is overall score, which range from 0 to 135, where lower score=no symptom and higher score=severe symptom. A decrease from baseline indicated improvement.

Baseline (Week 0), Week 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 24
時間枠:Baseline (Week 0), Week 24

Change from baseline in ESSPRI score at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjögren's Syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of Greater Than or Equal to (>=) 4 Points From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
時間枠:Baseline (Week 0), Week 24

ESSDAI covers 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, hematological) and 1 biological domain. Activity in each domain was scored at 3 to 4 level (no/low/moderate/high) according to severity as assessed by investigator based on criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain have 4 activity level). Each domain was assigned weight range from 1 to 6. Activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall ESSDAI score, ranging from 0 to 123 (0=no systemic disease activity, higher score indicated greater systemic disease activity). Decrease from baseline meant improvement.

Baseline (Week 0), Week 24
Percentage of Participants With Improvement of >= 4 Points From Baseline in clinESSDAI Score at Week 24
時間枠:Baseline (Week 0), Week 24

In clinESSDAI, physician score systemic disease activity level on 11 organ-specific domain (constitutional, lymphadenopathy and lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral nervous system, central nervous system, and hematological), with each domain activity in 3 to 4 level (no/low/moderate/high) according to their severity assessed by investigator based on predefined criteria. Activity-level score range from 0 to 3 (0=no activity, 3=high activity; not all domain include 4 activity level). Each domain was assigned weight from 1 to 7; activity-level score was multiplied by corresponding domain weight to get weighted domain score. Each domain had specific scoring range determined by its activity level and assigned weight. Sum of weighted domain score was overall score ranging from 0 to 135 (lower score=no symptom, higher score=severe symptom). Decrease from baseline indicated improvement.

Baseline (Week 0), Week 24
Percentage of Participants With ESSPRI Response Defined as a Decrease of One Point or a Decrease of >= 15 Percent (%) in the ESSPRI Score From Baseline at Week 24
時間枠:Baseline (Week 0), Week 24

Percentage of participants with ESSPRI response defined as a decrease of one point or a decrease of >= 15% from baseline at Week 24 was reported. The ESSPRI was a patient-reported assessment of the severity of dryness, fatigue, and pain associated with primary Sjogren's syndrome. Participants were asked to rate the severity of dryness, fatigue and pain over the past 2 weeks on a numeric rating scale (NRS), ranging from 0 "no symptom" to 10 "maximal imaginable" symptoms (dryness, fatigue, pain). Each domain was scored on scale of 0 to 10 (0 = no symptom at all and 10 = worst symptom imaginable). A total score was calculated as the mean of the 3 individual domain scores, where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where higher ESSPRI scores indicated more severe symptoms.

Baseline (Week 0), Week 24
Percentage of Participants With Disease Response According to the Sjögren's Tool for Assessing Response (STAR) Composite Score at Week 24
時間枠:At Week 24

Percentage of participants with disease response according to STAR composite score at Week 24 was reported. STAR was a composite endpoint assessing multiple clinically relevant disease features. A STAR response was defined as a composite score of >=5 points in the 5 STAR domains, with weighting in parentheses: (i) decrease of >=3 in clinESSDAI score (3), (ii) decrease of >=1 point or >=15% from baseline in ESSPRI score (3), (iii) abnormal Schirmer's test at baseline and increase of >=5 millimeter (mm)/normal Schirmer's test at baseline and no change to abnormal/abnormal ocular staining score at baseline and a decrease of >=2 points/normal ocular staining score at baseline and no change to abnormal (1), (iv) increase of >=25% in unstimulated whole saliva/any increase if score is 0 at baseline (1), (v) decrease of >=25% in rheumatoid factor/decrease of >=10% in immunoglobulin G (IgG) (1). Overall score was sum of all domain weight, which range from 0 to 9 (higher score = worse outcome).

At Week 24
Percentage of Participants With an Improvement in Disease Activity Level (DAL) by >= 1 Level in at Least One clinESSDAI or ESSDAI Domain at Week 24
時間枠:At Week 24

DAL=level of disease activity severity (no/low/moderate/severe) in each clinESSDAI/ESSDAI domain. In clinESSDAI, physician score DAL on 11 organ-specific domains (constitutional, lymphadenopathy, lymphoma, articular, muscular, cutaneous, glandular, pulmonary, renal, peripheral and central nervous system, hematological) with each domain activity in 3-4 level according to severity (0=no activity, 3=high activity; not all domains have 4 activity level). Each domain given weight: 1-7, activity level score * domain weight. Sum of weighted domain score was overall score (0-135: higher score=severe symptom). A decrease from baseline indicated improvement. Participants with improvement of >= 4 points (minimal clinically important improvement) were reported in this outcome measure. ESSDAI differs from clinESSDAI by adding biological domain that cover B-cell biomarker (elevated gamma-globulin/IgG level, low complement level, cryoglobulinemia, monoclonal gammopathy).

At Week 24
Percentage of Participants With Improvement From Baseline in >= 3 of 5 Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) Categories at Week 24
時間枠:At Week 24

Percentage of participants with improvement from baseline in >= 3 of 5 CRESS categories at Week 24 was reported. CRESS was a composite tool that incorporates measures of disease activity (clinESSDAI), symptoms (ESSPRI), glandular function and systemic inflammation to assess disease activity. A CRESS response was defined as a response in >= 3 of the following 5 categories: (i) clinESSDAI score less than (<) 5 (low disease activity), (ii) decrease of >= 1 point or >= 15% from baseline in ESSPRI score, (iii) abnormal Schirmer's test at baseline (<= 5 mm) and an increase of >= 5 mm, or normal Schirmer's test at baseline and no change to abnormal, (iv) increase of >= 25% in unstimulated whole saliva or any increase if score is 0 at baseline, (v) decrease of >= 25% in rheumatoid factor or decrease of >= 10% in IgG.

At Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through End of Study Visit
時間枠:Post first administration of study intervention (Week 0) up to Week 30

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Adverse Events of Special Interests (AESIs) Through End of Study Visit
時間枠:Post first administration of study intervention (Week 0) up to Week 30

Number of participants with AESIs were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. Treatment-emergent adverse events associated with the following situations were considered AESIs. (i) Infections that were severe or require IV anti-infective or operative/invasive intervention; (ii) Hypoalbuminemia with albumin < 20 grams per liter (g/L) (< 2.0 grams per deciliter [g/dL]); applicable to participants who had albumin greater than (>) 20 g/L at previous assessments. Those who entered with < 20 g/L and stayed below this level were not reported as an AESI. Those who entered with an albumin > 20 g/L or those who entered with albumin < 20g/L and then had an increase in albumin > 20 g/L which subsequently decreased to < 20 g/L were reported as an AESI.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Through End of Study Visit
時間枠:Post first administration of study intervention (Week 0) up to Week 30

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly or any situation deemed medically important by the investigator. Treatment-emergent SAEs were defined as SAEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With TEAEs Leading to Treatment Discontinuation Through End of Study Visit
時間枠:Post first administration of study intervention (Week 0) up to Week 30

Number of participants with TEAEs leading to treatment discontinuation were reported. AEs was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Vital Signs
時間枠:Post first administration of study intervention (Week 0) up to Week 30

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs parameters including temperature (< 36 degree Celsius and > 38 degree Celsius), pulse rate (<= 50 beats per minute [bpm] and with >= 15 bpm decrease from baseline and >= 120 bpm and with >= 15 bpm increase from baseline), and blood pressure (systolic blood pressure [SBP]: <= 90 millimeters of mercury [mmHg] and with >= 20 mmHg decrease from baseline and >= 160 mmHg and with >= 20 mmHg increase from baseline; diastolic blood pressure [DBP]: <= 50 mmHg and with >= 15 mmHg decrease from baseline and >= 100 mmHg and with >= 15 mmHg increase from baseline). Only those categories in which at least 1 participant had data were reported.

Post first administration of study intervention (Week 0) up to Week 30
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
時間枠:Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Laboratory parameters included hematology (platelet count [platelets: decrease > 20% and value < 100)], red blood cell count, hemoglobin, hematocrit, white blood cell count with differential [lymphocytes: decrease > 20% and value < 0.08], [leukocytes: decrease > 10% and value < 2.5], [neutrophils: increase > 30% and value > 0.90], [eosinophils: increase > 20% and value > 0.10]), serum chemistry (phosphate [decrease > 10% and value < 0.6), lipid panel (high-density lipoprotein [HDL] and low-density lipoprotein [LDL], creatine kinase: increase > 20% and value > 960, cholesterol: value >= 6.2), urinalysis, and blood coagulation. Participants were assessed at Weeks 2, 4, 8, 12, 16, 20, 24, 30 but only those categories and timepoints (Weeks 2, 4, 8, 12, 16, 24, 30) in which at least 1 participant had data were reported.

Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Serum Nipocalimab Concentration Over Time
時間枠:Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30

Serum concentrations of nipocalimab over time was reported. This outcome measure was planned to be analyzed for specified arms only.

Predose and postdose at Weeks 0, 2, 8, and 12, predose at Weeks 4, 16, 24, and 30
Change From Baseline in C-reactive Protein (CRP)
時間枠:Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30

Change from baseline in CRP were reported.

Baseline (Week 0), Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 30
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
時間枠:Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in ESR were reported. ESR was a composite outcome assessment that measures the degree of inflammation.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Total Immunoglobulin (Ig)G, IgG1, IgG2, IgG3, IgG4
時間枠:Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in total IgG, IgG1, IgG2, IgG3, IgG4 were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Change From Baseline in Autoantibodies : Anti-Sjogren's Syndrome Related Antigen A (Anti-Ro/SSA), Anti-Sjogren's Syndrome Related Antigen B (Anti-La/SSB), and Anti-Ro52/TRIM21
時間枠:Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30

Change from baseline in autoantibodies included anti-Ro60/SSA, anti-La/SSB, and anti-Ro52/tripartite motif-containing protein 21 (Anti-Ro52/TRIM21) were reported.

Baseline (Week 0), Weeks 2, 4, 8, 16, 24, and 30
Change From Baseline in Autoantibodies: Rheumatoid Factor (RF)
時間枠:Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30

Change from baseline in autoantibodies included RF were reported.

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, and 30
Number of Participants With Anti-drug Antibodies (ADAs) to Nipocalimab
時間枠:Baseline (Week 0) up to Week 30

Number of participants with ADA to nipocalimab were reported. The presence of ADA to nipocalimab in serum was determined by a sensitive and drug-tolerant electrochemiluminescence immunoassay (ECLIA) method. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30
Number of Participants With Neutralising Antibodies (NAbs) to Nipocalimab
時間枠:Baseline (Week 0) up to Week 30

Number of participants with NAbs were reported. Neutralising antibodies to nipocalimab were assessed using a non-cell based competitive ligand binding ECLIA assay. This outcome measure was planned to be analyzed for specified arms only.

Baseline (Week 0) up to Week 30

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年9月21日

一次修了 (実際)

2023年10月23日

研究の完了 (実際)

2023年11月30日

試験登録日

最初に提出

2021年7月9日

QC基準を満たした最初の提出物

2021年7月9日

最初の投稿 (実際)

2021年7月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年10月15日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する